Terpstra, L. C.
Altenburg, J.
Doodeman, H. J.
PiƱeros, Y. S. Sabogal
Lutter, R.
Heijerman, H. G. M.
Boersma, W. G.
Funding for this research was provided by:
Chiesi USA
AstraZeneca
GlaxoSmithKline
Article History
Received: 24 January 2023
Accepted: 18 April 2023
First Online: 29 April 2023
Declarations
:
: This study is a sub analysis of the BAT study. The BAT study protocol was reviewed and approved by independent ethics committees and institutional review boards from all the 14 participating centers. The study was performed in accordance with the Good Clinical Practice guidelines, the International Conference on Harmonization guidelines, and the most recent version of the Declaration of Helsinki. Written informed consent for participation and publication of our results was obtained from all the participants at the screenings visit. The BAT study is registered on Clinical trials.gov number: NCT00415350.
: Not applicable.
: RL reported grants paid to his institution from Foresee, Nutrileads, Longfonds, Chiesi and AstraZeneca. WGB reported grants paid to his institution from GlaxoSmithKline and reported consulting fee for adviesraad 2021 SOBI. JA reported grants paid to her institution from Longfonds. HH, LCT, HJD, YSP have nothing to disclose.